20^th Annual Pharma Middle East Congress November 11-12, 2019 Renaissance Polat Istanbul Hotel | Istanbul, Turkey

PharmaMiddleEast 2019 cordially invites each and every interested and enthusiastic participant from all over the world to take part in the 20^th Annual Pharma Middle East Congress, at Istanbul, Turkey during 11-12 of November 2019.

Pharma Middle East 2019 is the most suitable platform to explore ones’ scientific knowledge by sharing through their presentations and to build a robust network with the eminent people, key decision makers from all-around the academic institutions, Healthcare Institutes, Pharmaceutical, Biotech organizations of the world. The conference aims to build a strong belief that all other health and medical sciences can provide the healthy circumstances by the inter-bonding with the Pharmaceutical studies and sciences and hence the theme Explore the Alliance of Pharmaceutical & Health Sciences. ME Conferences organizes a 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contain over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1 Pharmacy and Pharmaceutical Sciences

Pharmacy is the science with the technique of preparing drugs and dispensing. It is a health-related profession that links medical sciences with chemical sciences and aims to ensure the secure and productive use of pharmaceutical drugs. Pharmacists are the specialist on the drug therapy and are the primary health professionals who enhance the use of medication for the benefit of the patients. Pharmaceutical Sciences is a dynamic and interdisciplinary field that aims to integrate basic principles of Inorganic and organic chemistry, engineering, biochemistry, and biology to understand the optimized drug delivery to the body and translate this integrated understanding into advanced and innovative therapies against human diseases and disorders.

Track 2 Anatomy and Pathophysiology

Human Anatomy is the scientific study of the Human body in detail. Anatomy involves the morphological study of different systems in the human body namely Respiratory, Nervous, Digestive, Endocrine, Reproductive, Urinary, Cardiac, etc… Anatomy also deals with the muscular system which gets supports through the skeletal system. Pathophysiology is a union of pathology with the physiology that can also be termed as Physiopathology. Pathology is a medical division that describes conditions that observed in a person in the diseased state whereas physiology is the biological study that describes operative functions or activities within an organism. Pathology describes the unusual or undesirable condition, whereas Pathophysiology deals with the functional changes associated with or resulting from disease or injury.

Track 3 Bioinformatics and Bio-materials

Bioinformatics is an integrative field that develops system and software tools for assimilation of biological data. As an interdisciplinary field of study, bioinformatics unites biology, computer science, information engineering, mathematics and statistics to analyse and explain biological data. Bioinformatics has been used for in silicon analyses of biological queries using arithmetical and statistical techniques. Biomaterials’ is a science that existing from 50 years, the biomaterial is a substance that has been managed to merge with biological systems for a medical purpose - either a therapeutic or a diagnostic one. The study of biomaterials is termed as biomaterials science or biomaterials engineering.

Track 4 Pharmacognosy & Botony

Pharmacognosy is the study of chemical constituents obtained from plant and natural sources. Pharmacognosy deals with herbal derived products, non-organic derivatives and also with excipients from plant or mineral origin. Cosmeceuticals and Neutraceuticals are also part of pharmacognosy. The study through pharmacognosy involves the biological background of crude drugs. Through metabolic activities, all plants produce some chemical called plant constituents. Depending on those active constituents’ quality and quantity pharmacognostic study takes place. Botany is the science of plant life and a branch of biology, also called plant science, plant biology or phytology.

Track 5 Nanotechnology in Pharmacy

Nanotechnology is a field that deals with studies on Nano-sized particles. The nanotechnology to the pharma is the commanding combination to produce effective drug formulations and advanced drug delivery systems. It includes nanomedicines, nanoparticles and their synthesis, targeted drug delivery, Pro-drug development, Physical pharmacy, Bio-pharmaceutics, membrane function and transport, Responsive delivery systems, and novel drug delivery systems in it. The pharmaceutical study of nanotechnology needs experts like medical practitioners, pharmaceutical researchers, laboratory professionals, learners, academicians, and industry that is involved in Medical, Pharmaceutical and clinical studies.

Track 6 Medicinal & Biological Chemistry

Medicinal Chemistry is a part of chemical sciences particularly related to synthetic organic chemistry and pharmacological studies and different other organic qualities, where they are included with a plan, substance mix and advancement for a market of pharmaceutical operators, or bio-dynamic particles. It is also termed as Pharmaceutical Chemistry. Specifically, regenerative science in its most regular work concentrating on little natural atoms includes natural science and parts of characteristic items and computational science in a close blend with a group of studies, enzymology and basic science, together going for the revelation and advancement of new remedial specialists. The medicinal chemistry also deals with hydrocarbons which are a crucial part of Pharmaceutical Studies.

Track 7 Pharmacological Studies

Pharmacology is the biological science that deals with what happens to and by the drugs in the human body. It deals with the synthesis of drug and its design, drug’s cellular and molecular mechanisms, cellular communication, drug-drug interactions, drug-food interactions, metabolism & catabolism, absorption, distribution, excretion of drugs, drug toxic effects. Pharmacological studies involve two major branches which are the Pharmacodynamics and the Pharmacokinetics where the first one deals with what drug does to the human body and the second one deal with what body does to the drug after it has been administered into the body.

Track 8 Insights of Cancer Pharmacology

Cancer pharmacology includes the study of the basic mechanisms of signal transduction associated with cell proliferation and apoptosis, the mechanisms of action of anti-neoplastic agents, the design and discovery of new medicines, basic mechanisms of DNA repair and damage tolerance and the development of innovative strategies for gene therapy. Cancer Pharmacology concentrates on developing experimental approaches to the clinical treatment of cancer through research that bridges the fields of molecular carcinogenesis, biochemical pharmacology, radiation biology, and clinical pharmacology.

Track 9 Clinical Pharmacy & Pharmaceutical Care

Clinical Pharmacy is the branch of pharmacy in which a PharmD graduate can provide the patient care that enhances the utilization of medicines and advances in well-being, health, and disease avoidance. Clinical pharmacists foster patients in all medicinal services settings yet the clinical pharmacy development at first started inside doctor's facilities and centres. Clinical pharmacists frequently work in a joint effort with doctors and other human services experts. Clinical pharmacists have broad instruction in the biomedical, pharmaceutical, socio-behavioural and clinical sciences. Most clinical pharmacists have a Doctor of Pharmacy degree and numerous have finished at least one years of post-graduate preparing as a general and additionally claim to fame pharma store residency.

Track 10 Pharmaceutical Biotechnology and Microbiology

Pharmaceutical biotechnology is the branch of Biotechnology that deals with pharmaceuticals and its principles to the development of drugs. A majority of therapeutic drugs in the present drug market are bio-formulations, such as antibodies, nucleic acid products and vaccines. Pharmaceutical Microbiology is the sciences that interconnect Microbiology with Pharmaceutical studies to ensure the drug formulations negativity to the microbial and foreign particles.

Track 11 Pharmaceutical Ethics & Regulatory Affairs

Pharmacists are the basic tool for the medicinal services multidisciplinary group of pharmacy. They help to assure that prescriptions are utilized as a part of the most secure and best way. The set of principles to direct basic leadership for drug specialist and to raise moral trustworthiness differs as according to the country and expert body that makes the rules. Drug Regulatory Affairs or Government Affairs is a profession within regulated endeavours like pharmaceuticals, medicinal gadgets, agrochemicals, vitality etc… Regulatory Affairs additionally have certain significance within the Healthcare industries, such as pharmaceuticals, medical devices, biologics and practical aliment.

Track 12 Future of Pharmacy & Pharmacists

The profession of pharmacy is a significant path between its conventional drug-dispensing identity and a pioneering clinical role with health care provider status, where the pharmacists are the bridges between pharmacy and public for drug prescribing and dispensing.  In the future pharmacists will not only dispense drugs but will also provide patient-centered, individualized pharmaceutical services, the pharmacist will be eligible to practice more clinically. With this new community practice arrangements, pharmacists will help to lower health care costs and improve patient health and safety.

Track 13 Genetics in Drug Discovery and Development

The genomics revolution, which has seemingly pervaded all of the biological and biomedical sciences, has brought about its most impressive advances in the pharmaceutical sciences. The technological advances in high-throughput DNA sequencing, in assessing gene expression for thousands of transcripts, and in RNA construFcts to silence specific genes have not only been the driving force behind genomic studies, but have also contributed to an emerging paradigm shift that is occurring in pharmacology, drug development, and pharmacotherapeutics. The molecular tools now readily available to laboratories have hastened the shift from drug development based largely on chemistry to one based on our growing biological knowledge of the physiological and molecular effects of compounds. It is now becoming possible with these tools to assess at the cellular level the nature of drug action, toxicity, and tolerance. Similarly, our understanding of human disease is being refined, which will lead to more precise therapeutic interventions based on more precise understandings of disease states.

Pharma Middle East 2019 provides the most determined platform to share one's knowledge and to explore the professional bonding between Pharma and health sciences. It is going to be a 2-day event to ensure network for clinical and medical excellence, scientific research advancements, global knowledge on pharma and medicine, evident transformations in drug designing and delivery, Innovative scientific techniques, new utilities of Pharmaceutical Sciences with all other health sciences at one place.

Role of Pharma in World:

Pharma companies have always interacted with consumers. They have marketed directly to users, especially in the U.S., and they involve patients in clinical trials. They thus have some limited experience with consumer-facing business models. In this new era, pharma companies will have to become more proactive with large communities of patients and go beyond lip service in meeting the needs of a wide swath of consumers.

Pharma Market Analysis:

Countries with the highest per capita in the Pharmaceutical Industry

The United States is leading with $339,694 million per capita through its pharmaceuticals market, followed by Japan in second place with $94,025 million and China in third place with $86,774 million.

Pharmaceutical products that were highly marketed in the year 2017:

The global market for individual drugs was given as per the below, and as per the chart it describes the respective drug’s market values in present economic year i.e., 2017 or 2018 in billion USD and expected growth rate by 2022 and 2023 and the CAGR is given in percentage growth.

1. Pharmaceutical excipients have its value of 6.8 billion USD in 2017 and it is expected to reach 8.7 billion USD by 2022 and its CAGR will be 4.9% from 2017-2022.
2. Lung Cancer therapeutics has its value of 17.9billion USD in 2018 and it is expected to reach 26.3 billion USD by 2023 and its CAGR will be 8.0% from 2018-2023.
3. Bioinformatics has its value of 6.4 billion USD in 2017 and it is expected to reach 16 billion USD by 2022 and its CAGR will be 20.0% from 2017-2022.
4. HIV therapeutics has its value of 22 billion USD in 2017 and it is expected to reach 27.1 billion USD by 2022 and its CAGR will be 8.0% from 2017-2022.
5. Lysosomal storage diseases have its value of 5.1 billion USD in 2018 and it is expected to reach 7.6 billion USD by 2023 and its CAGR will be 8.3% from 2018-2023.
6. Proteomics has its value of 7.9 billion USD in 2017 and it is expected to reach 16.8 billion USD by 2022 and its CAGR will be 16.2% from 2017-2022.
7. Antipsychotic drugs have its value of 13.2 billion USD in 2018 and it is expected to reach 14.5 billion USD by 2023 and its CAGR will be 1.9% from 2018-2023.
8. Protein analysis methods have its value of 11.6 billion USD in 2018 and it is expected to reach 19 billion USD by 2023 and its CAGR will be 10.4% from 2018-2023.
9. Cell-based assays technical and methods have its value of 20.1 billion USD in 2018 and it is expected to reach 32.7 billion USD by 2023 and its CAGR will be 10.2% from 2018-2023.

World’s highest revenue generators in the Pharmaceutical Industry- pharmaceutical Companies with the highest annual revenue in million US dollars

Pharma Societies and Association in the Middle East:

• Turkish Pharmacists' Association
• Pharmaceutical Industry Association of Turkey
• International Society for Pharmaceutical Engineering-Turkey Affiliate
• Istanbul Chemical Products Exporters’ Association (IKMIB)
• Pharmaceutical Manufacturers Association of Turkey
• Association of Research-Based Pharmaceutical Companies, Turkey
• Turkish Pharmaceutical Exporters
• Turkey, TPA.YC International Pharmaceutical Students' Federation
• Emirates Medical Association
• Pharmaceutical Egyptian Association
• Egyptian Pharmacists Co
• Egyptian Pharmacists Association ( EPA )
• Egyptian Pharmaceutical Students' Federation
• Egypt - FIP - International Pharmaceutical Federation
• Tanta Pharmaceutical Scientific Society
• Emirates Pharmacy Society: Pharma Regulatory Affairs
• EDA - Egyptian Drug Authority
• Foreign Trade Association Ltd., Egypt
• Saudi Pharmaceutical Society
• International Iraqi Medical Association (IIMA)
• Iraq Pharmaceutical Association
• Iraqi Community Pharmacists Association
• Iraqi Medical Association (UK)
• Gulf Pharmaceutical Industries Association
• Pharmacy Postgraduate Society (PPS), Qatar
• Iranian Medical Association Network
• Iranian Scientific Pharmaceutical Association
• Iranian Association of Pharmaceutical Scientists (IASP)
• Iran Pharmacy Specialists Society
• Kuwait Pharmaceutical Association
• The Pharmaceutical Association of Israel

US FDA Clearance for Trial of ET140202 Artemis T-Cell Therapy

US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ET140202 ARTEMIS T-cell therapy in AFP-positive patients which was announced by Eureka Therapeutics, a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies. The sample said to treat the conditions with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.

Eureka plans to initiate its Phase 1/2 US multicenter clinical trial in the first half of the year. To assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ET140202 they are conducting the Phase 1 dose escalation portion of the trial and a dose expansion phase is planned to follow the selection of a recommended Phase 2 dose.

Newer Drugs for Muscle cells Rejuvenation

A new promising drug has been developed and proven to increase in muscle size, strength and metabolic state by the researchers from Texas University Medical Branch.

Human (also same in animals) body loses the ability to repair and rebuild degenerating skeletal muscles with aging and it starts from around 35 Years resulting in decrease in the muscle mass, strength and functioning. It will increase the inactive living and dependency in elders. A protein in the muscle cells in the human body is responsible for the dysfunction the muscle cells in elders. They administrated the drug in smaller molecules to the injured mice to affect this muscle protein and to limit its function which decreases the muscle strength. This experiment and observation was carried out on mice with muscle injury and which was treated with a placebo at the initial stage and with the newly developed drug later to get the possible positive results towards increasing in the muscle strength.

More details are given at Biochemical Pharmacology.

New Invention to fight Cancer Metastasis

A new drug-free anti-platelet therapy which is reversible could lower the risk of clotting in blood and potentially prevent cancer metastasis. A study reported in Science Translational Medicine reveals that this therapeutic approach involves modification of human platelets to create "decoys" which are still capable of binding to some cells but will not mix-up or carry out the other regular platelet functions, including chemical signaling associated with the coagulation process.

Platelets play a crucial role in resisting the bleeding and help to protect against life-threatening bleeding. Even though the hyperactive platelets are able to contribute various disorders, including severe blood clots, heart disease and cancer, several anti-platelet drugs inhibits clotting and their effects are not easy to reverse the function, leaving patients in dangerous condition if they develop unexpected severe bleeding or are in need of an emergency surgical procedure.

Viagra to treat Heart Diseases through master Growth Regulator

mTOR, a protein receives signals from cell division process through internal sensors that measures nutrients and energy supply and directs the cell to take action. These molecular switch studies were applied on heart disorders like overworked heart (enlarging).  It is also have applications in diabetes, kidney and lung disease, cancer and autoimmune disorders.

The protein mTOR, stands for mechanistic target of rapamycin, is so important to normal cells yet also plays major roles in several diseases. It combines with other proteins to form a complex, the major one being known as mTORC1. Superiorly active mTORC1 is known to be bad for the heart and leads to damage and disease, and it is thought that having control over mTORC1 protein could effectively treat heart disease. Overworked hearts with too much active mTORC1 enlarge abnormally similar to body muscle that bulks up after carrying heavy weights.

There is another protein called Protein Kinase G, which protects heart tissue from damage and disease. The surprising discovery of scientists’ that is the protein kinase G blocked mTORC1, figured out the key regulator of mTORC1 called tuberin (dubbed TCS2 by researchers), which acts like an "antenna" for biochemical signals triggering or blocking cell growth, and regulating metabolism. Similar to many other proteins known to alter tuberin, Ranek found protein kinase G altered tuberin by adding phosphates to it, but in a previously unpredicted region that turned out to provide the sought after brake-like effect. Protein kinase G is also the target of drugs like sildenafil which is commonly known as Viagra.

FDA fires the companies for marketing the drugs of Alzheimer’s illegally

The FDA, is a superior agency established and run by the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The US food and Drug Administration posted almost 12 warning letters and some online advisory notices towards foreign and domestic companies which are handling these activities.

It was said that 17 companies were illegally marketing (selling) the drugs which used to treat Alzheimer’s disease which are not approved yet. Alzheimer's is a serious and complex disease and most challenging disease that has no cure, which is unfortunate. Any products making unproven drug claims could mislead consumers to believe that such therapies exist and keep them from accessing therapies. The companies were reported on selling the products on websites and social media platforms, have not been reviewed by the FDA and hence not proven safe and effective enough to treat the Alzheimer’s disease. They may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis and treatment.

Read more about the mutations of Cancer influences the Cell-receptors

New researches revealed how mutations in cancer cells influence the cell receptor taking lung and rectal cancers as referrals. The research done in two Sweden Medical institutes (Karolinska Institute and Uppsala University) in collaboration with UK and USA reported on group of G protein-coupled receptors called Class Frizzled (Class F).

These receptors on the cell membrane get activated by hormones/messenger molecules, which trigger a cascade of processes within. G protein-coupled receptors are one of the largest protein families in the human body and are already an established drug target for a wide range of diseases. An important subgroup of G protein-coupled receptors is the so-called Class F receptors, but to date they have not constituted a therapeutic target to any great extent.

More details are published in the Journal Nature Communications.